MedTrace Logo

Tiotropium In Exercise

NCT00525512 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 519

Last updated 2013-12-24

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Exercise

Interventions

DRUG

tiotropium 18 mcg

Oral inhalation once daily of 18mcg tiotropium via handihaler

DRUG

Placebo

Oral inhalation of once-daily placebo matching tiotropium via handihaler

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-06-30

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Germany
  • Italy
  • Portugal
  • Russia
  • Spain
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525512 on ClinicalTrials.gov